<DOC>
	<DOCNO>NCT01079234</DOCNO>
	<brief_summary>This trial conduct Europe United States America ( USA ) . The aim trial investigate efficacy safety NN1250 ( insulin degludec ) subject type 1 diabetes .</brief_summary>
	<brief_title>Comparison NN1250 With Insulin Glargine Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Type 1 diabetes 12 month longer , hereof last 3 month injection base therapy Current treatment basal insulin ( e.g . insulin glargine , insulin detemir , NPH insulin ) use one two daily injection three daily mealtime insulin injection ( e.g . insulin aspart , insulin lispro , insulin glulisine , human insulin ) use bolus insulin therapy HbA1c maximum 10.0 % central laboratory analysis Body Mass Index ( BMI ) equal 35.0 kg/m^2 Ability selfmanage insulin therapy assess confirmation ( verbal confirmation screen visit ) change insulin dose precede two month prior screen Ability willingness adhere protocol include performance self measure plasma glucose ( SMPG ) profile self adjustment insulin dos Use within last 3 month prior Visit 1 antidiabetic glucose lower drug insulin Cardiovascular disease , within last 6 month prior visit 1 , define : stroke ; decompensated heart failure New York Heart Association ( NYHA ) class III IV ; myocardial infarction ; unstable angina pectoris ; coronary arterial bypass graft angioplasty Uncontrolled treated/ untreated severe hypertension ( systolic blood pressure equal 180 millimetre ( mm ) mercury ( Hg ) and/or diastolic blood pressure equal 100 mmHg ) Pregnancy , breastfeeding , intention become pregnant use adequate contraceptive measure accord local requirement Cancer medical history cancer ( except basal cell skin cancer squamous cell skin cancer )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>